Company: BIAF
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001641172-25-013280
Chunk: 14

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 14
---
 reviewing and discussing at least annually the relationship between compensation and risk-management policies and practices;                                                                                                                                                                    |
| ● | reviewing at least annually all director compensation and benefits for service on the Board and Board committees and recommending any changes to the Board as necessary; and                                                                                                                    |
| ● | reporting regularly to the Board regarding the Compensation Committee’s actions and making recommendations to the Board as appropriate.                                                                                                                                                         |

Attendance at Board Meetings

During 2024, the Board held four meetings,
the Audit Committee held four meetings, the Compensation Committee held one meeting, and the Nominating and Corporate Governance Committee
held one meeting. During 2024, each current member of the Board of Directors attended at least 75% of the total number of Board
meetings and, to the extent applicable, of the total number of meetings held by all Board committees on which such director served. The
Board also took action on a number of occasions as needed without a physical meeting in the form of unanimous written consents.

Annual Meeting Attendance

Although the Company does not have a
formal policy regarding director attendance at annual stockholder meetings, directors are encouraged to attend annual stockholder meetings.
Three of our directors at that time attended the 2024 annual meeting of stockholders.

Code of Ethics and Business Conduct

The Company has adopted a Code of Ethics and Business
Conduct (“Code of Ethics”) applicable to all of the Company’s directors, officers, and employees. If we
amend or grant any waiver of a provision of our Code of Ethics that applies to our directors or executive officers, we will publicly disclose
such amendment or waiver on our website and as required by applicable law. A copy of the Code of Ethics is available on the Investor Relations
section of the Company’s website at ir.bioaffinitytech.com and can be accessed through the “Governance Documents”
hyperlink under the “Governance” tab. The information on the website is not and should not be considered part of this Proxy
Statement and is not incorporated by reference in this Proxy Statement.

| 8 |

Insider Trading Policy

The Company has adopted an amended and
restated insider trading policy (the “Trading Policy”) that is designed to promote compliance with federal
securities laws, rules, and regulations, as well as the rules and regulations of the Nasdaq Stock Market. The Trading Policy provides
our standards on trading and causing the trading of our securities while in possession of confidential information. It prohibits trading
in certain circumstances and applies to us and all of